10Mar 2018

CLINICAL OUTCOMES AFTER SWITCHING FROM PREMIXED INSULIN TO BASAL INSULIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN EVERYDAY CARE IN THE GULF REGION: THE I-TALENT STUDY.

  • Consultant Endocrinology in Endocrinology and Diabetes, American Hospital Dubai.
  • Head of the Endocrine unit, Al Jahra Hospital.
  • Medical Manager, Sanofi.
Crossref Cited-by Linking logo

  • Abstract
  • Keywords
  • References
  • Cite This Article as
  • Corresponding Author

Type 2 diabetes mellitus (T2DM) prevalence in the Middle East is one of the highest in the world and glycemic control is frequently poor. Switching from other insulin regimens to a basal insulin has been shown to improve glycemic control in Europe and North America, but the benefits of such a strategy in Middle Eastern populations have not been demonstrated sufficiently. Our study aimed to describe the evolution of glycemic control in patients with T2DM who switched from premixed insulin to insulin glargine 100 U/mL (Gla-100). A multicentre, prospective, observational study (i-Talent) conducted between 2012 and 2014. Data were collected at three routine visits at Months 0, 3 and 6 from thirty public and private hospital centres involved in the management of T2DM from the United Arab Emirates, Kuwait and Qatar participated in this study. At baseline, patients were switched to Gla-100 at the dose chosen by the physician. Oral antidiabetic drugs could also be prescribed. Overall, 440 people were enrolled and 357 were analysed (68.2% men; mean age: 50.5 ? 10.0 years). The primary outcome was the change in HbA1c from baseline to 6 months. Secondary endpoints included the proportion of patients reaching HbA1c target (<7%), insulin dose, weight change and hypoglycaemic events. We found that mean HbA1c levels decreased significantly from 9.3% ? 1.5% to 7.5% ? 0.8% at 6 months (p<0.001). 22.1% of patients achieved HbA1c target <7.0%. Mean daily Gla-100 dose at 6 months was 32.4 ? 10.7 U/day. A mean body weight reduction of 0.75 ? 3.7 kg was observed. Overall, 3.4% of participants (15/380) reported 33 hypoglycemic events. In conclusion, T2DM patients from the Gulf region, inadequately controlled on a premixed insulin regimen may benefit from a switch to a basal insulin strategy with insulin glargine. While improving clinical outcomes in everyday clinical practice, insulin glargine treatment was well tolerated with a low incidence of hypoglycemia and no gain in body weight.

  1. Aschner P, Sethi B, Gomez-Peralta F, et al. Insulin glargine compared with premixed insulin for management of insulin-naive type 2 diabetes patients uncontrolled on oral antidiabetic drugs: the open-label, randomized GALAPAGOS study. Journal of diabetes and its complications. 2015.
  2. Davies M, Sinnassamy P, Storms F, Gomis R, Group ALS. Insulin glargine-based therapy improves glycemic control in patients with type 2 diabetes sub-optimally controlled on premixed insulin therapies. Diabetes Res Clin Pract. 2008;79(2):368-375.
  3. Gary Deed et al., Use of 50/50 Premixed Insulin Analogs in Type 2 Diabetes: Systematic Review and Clinical Recommendations. Diabetes Therapy. 2017 Dec; 8(6): 1265?1296.
  4. Hammer H, Klinge A. Patients with type 2 diabetes inadequately controlled on premixed insulin: effect of initiating insulin glargine plus oral antidiabetic agents on glycaemic control in daily practice. International journal of clinical practice. 2007;61(12):2009-2018.
  5. International Epidemiologiocal Association - European Federation. Good Epidemiological Practice (GEP): proper conduct in epidemiology research.
  6. International Diabetes Federation. IDF Diabetes Atlas, sixth edition.
  7. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes care. 2012;35(6):1364-1379.
  8. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes care. 2015;38(1):140-149.
  9. Janka HU, Plewe G, Riddle MC, Kliebe-Frisch C, Schweitzer MA, Yki-Jarvinen H. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes care. 2005;28(2):254-259.
  10. Peterson GE. Intermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemir. Current medical research and opinion. 2006;22(12):2613-2619.
  11. Roach P, Trautmann M, Arora V, Sun B, Anderson JH, Jr. Improved postprandial blood glucose control and reduced nocturnal hypoglycemia during treatment with two novel insulin lispro-protamine formulations, insulin lispro mix25 and insulin lispro mix50. Mix50 Study Group. Clinical therapeutics. 1999;21(3):523-534.
  12. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87(1):4-14.
  13. Schiel R, Muller UA. Efficacy and treatment satisfaction of once-daily insulin glargine plus one or two oral antidiabetic agents versus continuing premixed human insulin in patients with Type 2 diabetes previously on long-term conventional insulin therapy: the SWITCH Pilot Study. Exp Clin Endocrinol Diabetes. 2008;116(1):58-64.
  14. Sharplin P, Gordon J, Peters JR, Tetlow AP, Longman AJ, McEwan P. Switching from premixed insulin to glargine-based insulin regimen improves glycaemic control in patients with type 1 or type 2 diabetes: a retrospective primary-care-based analysis. Cardiovasc Diabetol. 2009;8:9.
  15. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes care. 2004;27(5):1047-1053.
  16. Yki-Jarvinen H. Combination therapies with insulin in type 2 diabetes. Diabetes care. 2001;24(4):758-767.

[Hubert Penninckk, Sameer AL-Shammari and Ahmed Mansour. (2018); CLINICAL OUTCOMES AFTER SWITCHING FROM PREMIXED INSULIN TO BASAL INSULIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN EVERYDAY CARE IN THE GULF REGION: THE I-TALENT STUDY. Int. J. of Adv. Res. 6 (Mar). 774-781] (ISSN 2320-5407). www.journalijar.com

Dr. Hubert Penninckx
American Hospital Dubai

DOI:

Article DOI: 10.21474/IJAR01/6730      
DOI URL: https://dx.doi.org/10.21474/IJAR01/6730

Download Full Paper

Download PDF No. of Downloads: 13 | No. of Views: 89